Description
Product details
TRIOGLIMITERIS 1/0.2 Voglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg Introduction TRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism. Composition Voglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels. Glimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues. Metformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption. Mechanism of Action TRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control: Voglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals. Glimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels. Metformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity. Indications TRIOGLIMITERIS 1/0.2 is indicated for: Type 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient. Dosage and Administration The typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily. Dosage adjustments may be required based on individual patient response, blood glucose levels, and renal function. It is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes. Side Effects Common side effects of TRIOGLIMITERIS 1/0.2 may include: Hypoglycemia (especially when used in combination with insulin or other antidiabetic medications) Gastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort) Weight gain (mainly associated with sulfonylureas) More severe side effects can include: Allergic reactions (rash, itching, swelling) Lactic acidosis (rare but serious adverse effect associated with metformin use) Hepatic dysfunction (monitor liver function tests periodically) Precautions Use with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion. Regular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2. Avoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis. Drug Interactions TRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary. Conclusion TRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order NOW
